RENE.L Regulatory News (RENE)

2 Aug 2007 12:12

ReNeuron Group plc02 August 2007 Notification of increase in issued share capital Guildford, UK, 2 August 2007: ReNeuron Group plc (LSE: RENE.L) announces that on1 August 2007 it allotted and issued 16,476,190 new ordinary shares of 1 penceeach in connection with the acquisition of the business and assets of AmCyte andthe placing of new ordinary shares with investors to provide working capital forthe acquired business for at least the next year. Further details of suchacquisition and placing are set out in ReNeuron's press release of 27 July 2007. As at 1 August 2007 the enlarged issued share capital of ReNeuron Group plccomprised 154,167,534 ordinary shares of 1 pence each. Enquiries: ReNeuronMichael Hunt, Chief Executive Officer Tel: +44 (0) 1483 302560Dr John Sinden, Chief Scientific Officer Financial DynamicsDavid Yates Tel: +44 (0) 20 7831 3113Claire Rowell Collins Stewart Europe LimitedTim Mickley Tel : +44 (0)20 7523 8350 About ReNeuron ReNeuron is a leading, UK-based stem cell therapy business. It is applying itsnovel stem cell platform technologies in the development of ground-breaking stemcell therapies to serve significant and unmet or poorly-met clinical needs. ReNeuron has used its c-mycER technology to generate genetically stable stemcell lines from non-embryonic tissue sources. This technology platform hasmulti-national patent protection and is fully regulated by means of achemically-induced safety switch. Cell growth can therefore be completelyarrested prior to in vivo implantation. ReNeuron has filed for approval to commence initial clinical studies in the USwith its lead ReN001 stem cell therapy for chronic stroke disability. Thisrepresents the world's first such filing concerning a neural stem cell treatmentfor a major neurological disorder. There are an estimated 50 million strokesurvivors worldwide, approximately one half of which are left with permanentdisabilities. The annual health and social costs of caring for these patientsis estimated to be in excess of £5 billion in the UK and in excess of US$50billion in the US. ReNeuron has also generated pre-clinical efficacy data with its ReN005 stem celltherapy for Huntington's disease, a genetic and fatal neurodegenerative disorderthat affects around 1 in 10,000 people. This programme is in pre-clinicaldevelopment. In addition to its stroke and Huntington's disease programmes,ReNeuron is developing stem cell therapies for Parkinson's disease, Type 1diabetes and diseases of the retina. ReNeuron has also leveraged its stem cell technologies into non-therapeuticareas - its ReNcell(R) range of cell lines for use in research and in drugdiscovery applications in the pharmaceutical industry. ReNeuron's ReNcell(R)CXand ReNcell(R)VM neural cell lines are marketed worldwide under license byMillipore Corporation. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found atwww.reneuron.com. This information is provided by RNS The company news service from the London Stock Exchange